Versigent (NYSE:VGNT – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $45.1111.
A number of research firms recently weighed in on VGNT. BNP Paribas Exane began coverage on Versigent in a research report on Tuesday, April 28th. They set an “outperform” rating and a $41.00 target price on the stock. Wolfe Research initiated coverage on Versigent in a research report on Thursday, April 30th. They set an “outperform” rating and a $53.00 target price on the stock. Fox Advisors upgraded shares of Versigent to a “strong-buy” rating in a research note on Tuesday, April 7th. TD Cowen raised their price target on shares of Versigent from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of Versigent to a “hold” rating in a research note on Saturday, April 18th.
Get Our Latest Research Report on Versigent
Versigent Price Performance
Versigent (NYSE:VGNT – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $999.00 earnings per share for the quarter.
See Also
- Five stocks we like better than Versigent
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
